8th ASM Biodefense & Emerging Diseases Conference
For the third time in less than 2 years Pherecydes Pharma is presenting at a biofense conferences, in the USA.
Hôpital Robert Debré collaboration
On February 7th, 2010, Robert Debré Hospital (Paris-France) and Pherecydes Pharma signed an agreement to select bacteriophage variants for eradicating different Escherichia coli strains.
R&D strategy
Pherecydes Pharma currently holds two patents. A third one has been filed mid 2009
- TAPE is a method for creating high diversity in DNA sequences while keeping intact domains.
- AB-ACCUS is a rapid and efficient technology to produce phage banks in which every individual differs from all others.
- RIPh (patent pending) is a methodology allowing reversible interruption of virulent phage lytic cycle.